MANUEL ALEJANDRO ROMERO MARTÍNEZ-rekin lankidetzan egindako argitalpenak (7)

2016

  1. The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators

    Journal of Medicinal Chemistry, Vol. 59, Núm. 21, pp. 9967-9973

2014

  1. Neuroprotective effect of dimebon against ischemic neuronal damage

    Neuroscience, Vol. 267, pp. 11-21

  2. Neuroprotective effect of melatonin against ischemia is partially mediated by alpha-7 nicotinic receptor modulation and HO-1 overexpression

    Journal of Pineal Research, Vol. 56, Núm. 2, pp. 204-212

2013

  1. Novel multitarget ligand ITH33/IQM9.21 provides neuroprotection in in vitro and in vivo models related to brain ischemia

    Neuropharmacology, Vol. 67, pp. 403-411

2011

  1. Calcium signalling mediated through α7 and non-α7 nAChR stimulation is differentially regulated in bovine chromaffin cells to induce catecholamine release

    British Journal of Pharmacology, Vol. 162, Núm. 1, pp. 94-110

  2. N-Acylaminophenothiazines: Neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 46, Núm. 6, pp. 2224-2235

2010

  1. Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives

    Journal of Medicinal Chemistry, Vol. 53, Núm. 14, pp. 5129-5143